AIX Inc. Price & Performance (AIFU)

CG Oncology is presenting pivotal findings at the European Association of Urology Congress in Madrid. Highlights include late-breaking data from the BOND-003 trial and insights into cretostimogene grenadenorepvec, a bladder-sparing treatment. The event underscores the company’s commitment to advancing bladder cancer therapeutics.12

AIX has until August 25, 2025, to address Nasdaq’s minimum bid price rule after trading below $1.00 per share for 30 days. The company may consider a reverse stock split to regain compliance. Failure to meet the requirement could lead to delisting, though an extension remains possible.34

Veeam has released a patch for a high-risk flaw in its Backup and Replication software. The vulnerability, rated 9.9 out of 10, could allow authenticated users to execute arbitrary code. Experts urge immediate updates to mitigate risks, as the issue highlights ongoing challenges in software security.5